Spinifex Pharmaceuticals is a private, venture capital backed company, supported by a syndicate of experienced life science investors.
Investors

GBS Venture Partners
GBS Venture Partners is Australia’s leading life science venture capital group with in excess of $400 million under management. GBS invests from seed through early expansion stage and has invested in more than 30 life science companies.
www.gbsventures.com.au

Brandon Capital Partners
Brandon Capital Partners makes seed and venture capital investments into emerging businesses in the high-growth life science industry. Brandon Capital Partners’ team has a track record of successful life science investment as well as a history of working in research, operations and business development in the healthcare industry.
www.brandoncapital.com.au

Uniseed
Uniseed is a $60 million commercialisation fund operating at the Universities of Melbourne, New South Wales and Queensland. Apart from these three universities, AustralianSuper, one of Australia’s largest and best performing industry superannuation funds, is also a member. Uniseed has made over 30 investments in technologies arising from its three partner universities including Vintela (AVCAL Best Early-Stage Deal 2005) and QRxPharma Ltd (largest biotech IPO in ASX history).
www.uniseed.com

Uniquest
Established by The University of Queensland in 1984, UniQuest is widely recognised as one of Australia’s largest and most successful university commercialisation groups, benchmarking in the top tier of technology transfer worldwide. From an intellectual property portfolio of 1,500+ patents it has created over 60 companies, and since 2000 UniQuest and its start-ups have raised more than $400 million to take university technologies to market. Annual sales of products using UQ technology and licensed by UniQuest are running at $3 billion. UniQuest now commercialises innovations developed at The University of Queensland and its commercialisation partner institutions: the University of Wollongong, University of Technology Sydney, James Cook University, University of Tasmania, Mater Medical Research Institute, and Queensland Health.
www.uniquest.com.au
Latest News & Events
27TH MARCH 2013 Spinifex Receives $1.5m in R&D Tax Incentive for Research Activities Related to the Discovery of ... More
30TH JANUARY 2013 Pivotal EMA401 mechanism of action data has now been published in the European Journal of ... More
10TH DECEMBER 2012 Spinifex Initiates Phase 2 Proof-Of-Concept Clinical Trial in Chemotherapy Induced Neuropathy ... More